Skip to main content

Orserdu Dosage

Generic name: ELACESTRANT 86mg
Dosage form: tablet, film coated
Drug classes: Estrogen receptor antagonists, Hormones / antineoplastics

Medically reviewed by Drugs.com. Last updated on Aug 2, 2024.

Patient Selection

Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with ORSERDU based on the presence of ESR1 mutation(s) in plasma specimen using an FDA-approved test.

Information on FDA-approved tests for detection of ESR1 mutations in breast cancer is available at: http://www.fda.gov/CompanionDiagnostics.

Recommended Dosage

The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs.

Take ORSERDU at approximately the same time each day. Take with food to reduce nausea and vomiting.

Swallow ORSERDU tablet(s) whole. Do not chew, crush, or split prior to swallowing. Do not take any ORSERDU tablets that are broken, cracked, or that look damaged.

If a dose is missed for more than 6 hours or vomiting occurs, skip the dose and take the next dose the following day at its regularly scheduled time.

Dosage Modifications for Adverse Reactions

The recommended dose reduction levels for adverse reactions are listed in Table 1:

Table 1: ORSERDU Dose Reduction Levels for Adverse Reactions

1 If further dose reduction below 172 mg once daily is required, permanently discontinue ORSERDU.
Dose Reduction Dosage Number and Strength of Tablets
First-dose reduction 258 mg once daily Three 86 mg tablets
Second-dose reduction 172 mg once daily1 Two 86 mg tablets

Recommended dosage modifications of ORSERDU for adverse reactions are provided in Table 2.

Table 2: ORSERDU Dosage Modification Guidelines for Adverse Reactions

Severity Dosage Modification
Grade 1 Continue ORSERDU at current dose level.
Grade 2 Consider interruption of ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU at the same dose level.
Grade 3 Interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU at the next lower dose level.

If the Grade 3 toxicity recurs, interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU reduced by another dose level.
Grade 4 Interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU reduced by one dose level.

If a Grade 4 or intolerable adverse reaction recurs, permanently discontinue ORSERDU.

Dosage Modifications for Use with Concomitant CYP3A4 Inducers and Inhibitors

Avoid concomitant use of ORSERDU with strong or moderate CYP3A4 inducers and inhibitors.

Dosage Modifications for Hepatic Impairment

Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the ORSERDU dosage to 258 mg once daily for patients with moderate hepatic impairment (Child-Pugh B). No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.